Epidemiology, Symptoms, and Treatment Characteristics of
... Age and female sex are established major risk factors for treatment-emergent hyponatremia. Moreover, in psychiatry, special patient populations are at particular risk to develop this type of electrolyte disturbance. These include mainly schizophrenia patients with polydipsia or others with compulsiv ...
... Age and female sex are established major risk factors for treatment-emergent hyponatremia. Moreover, in psychiatry, special patient populations are at particular risk to develop this type of electrolyte disturbance. These include mainly schizophrenia patients with polydipsia or others with compulsiv ...
A Guideline for the Clinical Management of Opioid Use Disorder
... for persons, justice and accountability, as well as the required standards for good clinical practice of the College of Physicians and Surgeons of BC and any other relevant governing bodies. The application of the recommendations in this guideline does not override the responsibility of health care ...
... for persons, justice and accountability, as well as the required standards for good clinical practice of the College of Physicians and Surgeons of BC and any other relevant governing bodies. The application of the recommendations in this guideline does not override the responsibility of health care ...
An Evidence-Based Approach To The Evaluation And
... The symptoms of croup are caused by infiltration of the subglottic region of the larynx by an infectious pathogen. This infiltration causes erythema, edema, and glandular hypersecretion of the subglottic mucosa. Because this narrowest part of the pediatric airway is bound by a complete ring of carti ...
... The symptoms of croup are caused by infiltration of the subglottic region of the larynx by an infectious pathogen. This infiltration causes erythema, edema, and glandular hypersecretion of the subglottic mucosa. Because this narrowest part of the pediatric airway is bound by a complete ring of carti ...
INVOKAMET® XR
... the kidney [see Clinical Pharmacology (12.3)]. • Before initiating INVOKAMET XR, obtain an estimated glomerular filtration rate (eGFR). • INVOKAMET XR is contraindicated in patients with an eGFR less than 45 mL/minute/1.73 m2. • Obtain an eGFR at least annually in all patients taking INVOKAMET X ...
... the kidney [see Clinical Pharmacology (12.3)]. • Before initiating INVOKAMET XR, obtain an estimated glomerular filtration rate (eGFR). • INVOKAMET XR is contraindicated in patients with an eGFR less than 45 mL/minute/1.73 m2. • Obtain an eGFR at least annually in all patients taking INVOKAMET X ...
A Multi-Center, Randomized, Double Blind, Phase III Trial
... 7. Other drugs for GVHD treatment 8. If any prior steroid therapy (for indication other than GVHD), treatment at doses > 0.5 mg/kg/day methyl-prednisolone within 7 days prior to onset of GVHD. 9. Patients who are pregnant, breast feeding, or if sexually active, unwilling to use effective birth contr ...
... 7. Other drugs for GVHD treatment 8. If any prior steroid therapy (for indication other than GVHD), treatment at doses > 0.5 mg/kg/day methyl-prednisolone within 7 days prior to onset of GVHD. 9. Patients who are pregnant, breast feeding, or if sexually active, unwilling to use effective birth contr ...
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) PAEDIATRIC POPULATION
... development and ability to co-ordinate, but also to psychological development and understanding. The ability to effectively use different inhaler devices illustrates this well with a gradual progression from holding a chamber with mask, spacer, breath-activated device and metered dose inhaler from i ...
... development and ability to co-ordinate, but also to psychological development and understanding. The ability to effectively use different inhaler devices illustrates this well with a gradual progression from holding a chamber with mask, spacer, breath-activated device and metered dose inhaler from i ...
Guidelines for the physiotherapy management of the adult
... improvement or maintenance, and airway clearance and cough enhancement or support. Strategies and techniques include: rehabilitation, exercise testing (including for ambulatory oxygen assessment), exercise prescription, airway clearance, and positioning and breathing techniques. Physiotherapy may be ...
... improvement or maintenance, and airway clearance and cough enhancement or support. Strategies and techniques include: rehabilitation, exercise testing (including for ambulatory oxygen assessment), exercise prescription, airway clearance, and positioning and breathing techniques. Physiotherapy may be ...
INFORMATION TO THE PATIENT
... paternalistic treatment. But patients might not be totally different from the rest or us, in that all their human capacities for autonomous action are limited. Boverman (1983) examined whether informed consent could be harmful or hazardous, or whether this moral and legal requirement was, in fact, a ...
... paternalistic treatment. But patients might not be totally different from the rest or us, in that all their human capacities for autonomous action are limited. Boverman (1983) examined whether informed consent could be harmful or hazardous, or whether this moral and legal requirement was, in fact, a ...
CIPRO
... unchanged ciprofloxacin. Excretion: The serum elimination half-life in subjects with normal renal function is approximately 4 hours. Approximately 40 to 50% of an orally administered dose is excreted in the urine as unchanged drug. After a 250 mg oral dose, urine concentrations of ciprofloxacin usua ...
... unchanged ciprofloxacin. Excretion: The serum elimination half-life in subjects with normal renal function is approximately 4 hours. Approximately 40 to 50% of an orally administered dose is excreted in the urine as unchanged drug. After a 250 mg oral dose, urine concentrations of ciprofloxacin usua ...
KNGF Guideline - Dutch Society of Neuro Rehabilitation
... The incidence of stroke increases with advancing age, and is estimated to be 45,000 a year in the Netherlands. The prevalence has also risen in recent years and was estimated at 226,600 in 2007. In view of the current increase in life expectancy and the aging of the population in the Netherlands, th ...
... The incidence of stroke increases with advancing age, and is estimated to be 45,000 a year in the Netherlands. The prevalence has also risen in recent years and was estimated at 226,600 in 2007. In view of the current increase in life expectancy and the aging of the population in the Netherlands, th ...
Gerovital H3 - Longevity Formulas
... II. Circulation: Circulation is the second major area of health maintenance believed to be improved by GH3. Studies show that Gerovital tends gently to dilate and cleanse blood vessels.23 Obviously, many conditions of decaying health accompany a reduction in circulation. In some cases, cardiac patie ...
... II. Circulation: Circulation is the second major area of health maintenance believed to be improved by GH3. Studies show that Gerovital tends gently to dilate and cleanse blood vessels.23 Obviously, many conditions of decaying health accompany a reduction in circulation. In some cases, cardiac patie ...
Management of Adults With Hospital
... Grant W. Waterer,19 Peggy Cruse,20 Shandra L. Knight,20 and Jan L. Brozek21 ...
... Grant W. Waterer,19 Peggy Cruse,20 Shandra L. Knight,20 and Jan L. Brozek21 ...
Prograf®
... young children who are at risk for primary EBV infection while immunosuppressed, or who are switched to Prograf following long-term immunosuppression therapy. Experience on combining Prograf with immunosuppressive drugs other than adrenal corticosteroids, azathioprine and mycophenolate mofetil is li ...
... young children who are at risk for primary EBV infection while immunosuppressed, or who are switched to Prograf following long-term immunosuppression therapy. Experience on combining Prograf with immunosuppressive drugs other than adrenal corticosteroids, azathioprine and mycophenolate mofetil is li ...
Clinical Practice Guideline for the Management - LIFE
... 25. Therapy should continue until lesions resolve on repeat imaging, which is usually several months. Premature discontinuation of antifungal therapy can lead to relapse (strong recommendation; low-quality evidence). 26. If chemotherapy or hematopoietic cell transplantation is required, it should no ...
... 25. Therapy should continue until lesions resolve on repeat imaging, which is usually several months. Premature discontinuation of antifungal therapy can lead to relapse (strong recommendation; low-quality evidence). 26. If chemotherapy or hematopoietic cell transplantation is required, it should no ...
PDF hosted at the Radboud Repository of the Radboud University
... designs in behaviour therapy research has led to a careful investigation of the effectiveness of alternative treatment programmes and behavioural techniques, but treatment outcome variance possibly related to treatments factors other than those specified in the experimental conditions, again, tends ...
... designs in behaviour therapy research has led to a careful investigation of the effectiveness of alternative treatment programmes and behavioural techniques, but treatment outcome variance possibly related to treatments factors other than those specified in the experimental conditions, again, tends ...
Ann. Emerg. Safty of phenylpropanolismine. 66 b.
... were recorded at 0, 0.5, 1, and 2 hours after dosing on days 1, 2, and 3, and every hour for 12 hours on day 4. Blood was taken at various intervals during day 4; plasma concentrations of phenylpropanolamine were measured* ...
... were recorded at 0, 0.5, 1, and 2 hours after dosing on days 1, 2, and 3, and every hour for 12 hours on day 4. Blood was taken at various intervals during day 4; plasma concentrations of phenylpropanolamine were measured* ...
Harrison`s Principles of Internal Medicine, 17
... Oral colchicine has long been used, although it has only recently (in 2009) been approved by the Food and Drug Administration (FDA) for use in patients with acute gout. In a randomized trial, colchicine (at a dose of 1.2 mg at the onset of a flare, followed by 0.6 mg 1 hour later) was significantly ...
... Oral colchicine has long been used, although it has only recently (in 2009) been approved by the Food and Drug Administration (FDA) for use in patients with acute gout. In a randomized trial, colchicine (at a dose of 1.2 mg at the onset of a flare, followed by 0.6 mg 1 hour later) was significantly ...
UAA Consensus on the LUTS Edition)
... are the most prevalent, highly validated questionnaire for BPH patients [1-4]. Freuqeuncy volume chart (time and volume of voids and including any episodes of incontinence) or a bladder diary (a 24 hour recording of your liquid intake and urine output) is recommended for men with daytime or nocturna ...
... are the most prevalent, highly validated questionnaire for BPH patients [1-4]. Freuqeuncy volume chart (time and volume of voids and including any episodes of incontinence) or a bladder diary (a 24 hour recording of your liquid intake and urine output) is recommended for men with daytime or nocturna ...
What is Porphyria? - Welsh Medicines Information Centre
... experience suggests that administration of haem arginate in 100mL human albumin helps reduce these problems,10 and this has become accepted practice in several countries (e.g. South Africa and France). There currently appears to be no formal consensus on what strength of human albumin to use and bet ...
... experience suggests that administration of haem arginate in 100mL human albumin helps reduce these problems,10 and this has become accepted practice in several countries (e.g. South Africa and France). There currently appears to be no formal consensus on what strength of human albumin to use and bet ...
Product Monograph November 8, 2016
... 2 and No. 3 as it may increase the chance of experiencing serious adverse events, including death. Hyperalgesia that will not respond to a further dose increase of opioids can occur at particularly high doses. A codeine dose reduction or change in opioid may be required. Patients should be counselle ...
... 2 and No. 3 as it may increase the chance of experiencing serious adverse events, including death. Hyperalgesia that will not respond to a further dose increase of opioids can occur at particularly high doses. A codeine dose reduction or change in opioid may be required. Patients should be counselle ...
Harrison`s Principles of Internal Medicine, 17
... Oral colchicine has long been used, although it has only recently (in 2009) been approved by the Food and Drug Administration (FDA) for use in patients with acute gout. In a randomized trial, colchicine (at a dose of 1.2 mg at the onset of a flare, followed by 0.6 mg 1 hour later) was significantly ...
... Oral colchicine has long been used, although it has only recently (in 2009) been approved by the Food and Drug Administration (FDA) for use in patients with acute gout. In a randomized trial, colchicine (at a dose of 1.2 mg at the onset of a flare, followed by 0.6 mg 1 hour later) was significantly ...
Improvement of post-hypoxic action myoclonus with
... on the clinical ground alone. In chronic PAM, myoclonus is noted within a few days to some months after the acute episode. The myoclonus may be accompanied by dysmetria, dysarthria and ataxia, with relatively preserved higher cognitive functions 2, 3. Several types of myoclonus can be observed in th ...
... on the clinical ground alone. In chronic PAM, myoclonus is noted within a few days to some months after the acute episode. The myoclonus may be accompanied by dysmetria, dysarthria and ataxia, with relatively preserved higher cognitive functions 2, 3. Several types of myoclonus can be observed in th ...
Overview of COPD
... 10maintenance therapy, refer pulmonary rehab, minimize exacerbation, review aggravating factors: smoking ...
... 10maintenance therapy, refer pulmonary rehab, minimize exacerbation, review aggravating factors: smoking ...
Management of multiple sclerosis
Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS).The most common initial course of the disease is the relapsing-remitting subtype, which is characterized by unpredictable attacks (relapses) followed by periods of relative remission with no new signs of disease activity. After some years, many of the people who have this subtype begin to experience neurologic decline without acute relapses. When this happens it is called secondary progressive multiple sclerosis. Other, less common, courses of the disease are the primary progressive (decline from the beginning without attacks) and the progressive-relapsing (steady neurologic decline and superimposed attacks). Different therapies are used for patients experiencing acute attacks, for patients who have the relapsing-remitting subtype, for patients who have the progressive subtypes, for patients without a diagnosis of MS who have a demyelinating event, and for managing the various consequences of MS.The primary aims of therapy are returning function after an attack, preventing new attacks, and preventing disability. As with any medical treatment, medications used in the management of MS may have several adverse effects, and many possible therapies are still under investigation. At the same time different alternative treatments are pursued by many patients, despite the paucity of supporting, comparable, replicated scientific study.This article focuses on therapies for standard MS; borderline forms of MS have particular treatments that are excluded.